Tag: quarter

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, July 31, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report second quarter financial results, before the US markets open on Thursday, August 7, 2025.

Q2 2025 RESULTS¹
Net income group share at EUR 271 million, up 38.5% vs. Q2 2024

SCOTTSDALE, Ariz., July 30, 2025 (GLOBE NEWSWIRE) -- Caliber (NASDAQ: CWD), a real estate investor, developer, and manager, today announced that it will release its second quarter 2025 financial results after the close of the stock market on Wednesday, August 13, 2025. Management invites all interested parties to its webcast/conference call the same day at 5:00 pm ET to discuss the results.

CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 38,000,000 shares of its common stock at a public offering price of $3.30 per share. The underwriters will not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 5,700,000 shares of its common stock. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $125.4 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares of common stock in the offering are to be sold by Prime Medicine. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions.

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Match Group, Inc. (NASDAQ: MTCH) on behalf of long-term stockholders following a class action complaint that was filed against Match Group on November 13, 2024 with a Class Period from May 2, 2023 to November 6, 2024. Our investigation concerns whether the board of directors of Match Group have breached their fiduciary duties to the company.

Capitalized terms that are used but not defined in this news release have the meaning ascribed to those terms in Management's Discussion & Analysis for the three and six months ended June 30, 2025.

Bragar Eagel & Squire, P.C. Litigation Attorney Brandon Walker Encourages Investors Who Suffered Losses In Fiserv (FI) To Contact Him Directly To Discuss Their Options

- Expects to reduce 2024 net loss and increase carrying value of assets held for sale
by approximately $2.2 million -
- Expects to increase first quarter 2025 net income by approximately $0.5 million, resulting in a cumulative increase in carrying value of assets held for sale by approximately $2.7 million -
- No change to 2024 or first quarter 2025 Adj. EBITDA -

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

BOLTON, Ontario, July 30, 2025 (GLOBE NEWSWIRE) -- Titanium Transportation Group Inc. ("Titanium" or the "Company") (TSX:TTNM, OTCQX:TTNMF), is pleased to announce that it will issue its financial results for the quarter ended June 30, 2025 via news release on Monday, August 11, 2025 after market close.